BioMarin Prices $850M Senior Notes and Completes Syndication for $2B Term Loan B to Fund Amicus Acquisition
Summary
BioMarin Pharmaceutical Inc. announced the pricing of $850 million in senior unsecured notes and the completion of syndication for a $2 billion senior secured term loan B facility, both intended to fund the pending acquisition of Amicus Therapeutics, Inc.
Key Events
-
Senior Notes Priced
BioMarin priced $850 million of 5.500% senior unsecured notes due 2034 in a private placement, with the offering expected to close on February 12, 2026. This finalizes terms for a portion of the debt financing package initiated on January 26, 2026.
-
Term Loan B Syndication Completed
The company completed the syndication of a new $2 billion senior secured term loan "B" facility, which is part of a larger senior secured credit facility package.
-
Acquisition Funding Secured
Proceeds from the notes and term facilities, along with cash on hand, will fund the pending acquisition of Amicus Therapeutics, Inc. and related fees and expenses.
Analysis
This 8-K provides critical updates on BioMarin's substantial debt financing package, which was previously announced on January 26, 2026. It finalizes the terms and pricing of $850 million in senior unsecured notes at 5.500% and confirms the completion of syndication for the $2 billion Term Loan B facility. These are significant steps in securing the necessary capital for the Amicus Therapeutics acquisition. While increasing the company's debt load, the successful execution of this financing demonstrates market confidence and ensures funding for a key strategic growth initiative. Investors should monitor the closing of the acquisition and the integration of Amicus.
At the time of this filing, BMRN was trading at $57.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $50.76 to $73.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.